IMVAMUNE®

BIOLOGICAL3 trials

Sponsors

Bavarian Nordic

Conditions

SmallpoxVaccination

Phase 2

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

CompletedNCT02038881

Bavarian NordicSmallpox

Start: 2014-04-28End: 2017-05-10Updated: 2020-04-02

Phase 3

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

CompletedNCT01144637

Bavarian NordicSmallpox

Start: 2013-02-28End: 2014-06-30Updated: 2019-01-03

Phase 4

Special Access Program IMVAMUNE®

CompletedNCT03472014

Bavarian NordicVaccination

Start: 2010-04-22End: 2014-11-14Updated: 2020-08-19

Related Papers

A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS.

2020-02-1153 citations

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PLoS ONE2018-04-1364 citations